These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 29097496)

  • 1. Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.
    Voruz S; Cairoli A; Naveiras O; de Leval L; Missiaglia E; Homicsko K; Michielin O; Blum S
    Haematologica; 2018 Jan; 103(1):e39-e41. PubMed ID: 29097496
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma".
    Voruz S; Martins F; Cairoli A; Naveiras O; Homicsko K; Missiaglia E; de Leval L; Bisig B; Michielin O; Blum S
    Haematologica; 2018 Mar; 103(3):e130. PubMed ID: 29491129
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeted therapy of BRAF V600E-mutant histiocytic sarcoma: A case report and review of the literature.
    Branco B; Comont T; Ysebaert L; Picard M; Laurent C; Oberic L
    Eur J Haematol; 2019 Oct; 103(4):444-448. PubMed ID: 31376203
    [No Abstract]   [Full Text] [Related]  

  • 4. A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.
    Kumamoto T; Aoki Y; Sonoda T; Yamanishi M; Arakawa A; Sugiyama M; Shirakawa N; Ishimaru S; Saito Y; Maeshima A; Maeda M; Ogawa C
    Int J Hematol; 2019 Feb; 109(2):228-232. PubMed ID: 30361829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting MEK in a Translational Model of Histiocytic Sarcoma.
    Takada M; Hix JML; Corner S; Schall PZ; Kiupel M; Yuzbasiyan-Gurkan V
    Mol Cancer Ther; 2018 Nov; 17(11):2439-2450. PubMed ID: 30135215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Would you think of histiocytic sarcoma in this fine-needle aspiration?
    Oliveira CC; Rocha JTQ; Silva GF; Biglia B; Gaiolla RD; Niero-Melo L; Domingues MAC
    Ann Hematol; 2018 Nov; 97(11):2257-2259. PubMed ID: 29728735
    [No Abstract]   [Full Text] [Related]  

  • 7. Histiocytic sarcoma of the thyroid.
    Munoz J; Sanchez BE; Wang D
    Am J Hematol; 2012 May; 87(5):531. PubMed ID: 22121014
    [No Abstract]   [Full Text] [Related]  

  • 8. Leukemic Phase of Histiocytic Sarcoma of the Digestive System: A Rare Manifestation of a Rare Disease.
    Hofstetter L; Aranovich D; Bernstine H; Hayman L; Shahal-Zimra Y; Rabizadeh E; Cohen A; Lahav M; Raanani P; Wolach O
    Acta Haematol; 2021; 144(2):229-235. PubMed ID: 33017829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary Orbital Histiocytic Sarcoma in a Child Successfully Treated With Multiagent Chemotherapy.
    Mittal N; Aakalu V; Mehendele S; Setabutr P; Michals E; Schmidt ML
    J Pediatr Hematol Oncol; 2016 Nov; 38(8):653-657. PubMed ID: 27467374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose methotrexate-based chemotherapy as treatment for histiocytic sarcoma of the central nervous system.
    Curry RC; Faivre G; Akkari L; Joyce JA; Lin O; Rosenblum M; Diamond EL; Fisher R; Omuro A
    Leuk Lymphoma; 2016 Aug; 57(8):1961-4. PubMed ID: 26727454
    [No Abstract]   [Full Text] [Related]  

  • 11. Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation.
    Gounder MM; Solit DB; Tap WD
    N Engl J Med; 2018 May; 378(20):1945-1947. PubMed ID: 29768143
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful treatment of histiocytic sarcoma with cladribine and high-dose cytosine arabinoside in a child.
    Iwabuchi H; Kawashima H; Umezu H; Takachi T; Imamura M; Saitoh A; Ogose A; Imai C
    Int J Hematol; 2017 Aug; 106(2):299-303. PubMed ID: 28247189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Collision tumor of small lymphocytic lymphoma and histiocytic sarcoma: report of a case].
    Gao LX; Liu G; Yang GZ; Ding HY
    Zhonghua Bing Li Xue Za Zhi; 2009 Nov; 38(11):775. PubMed ID: 20079020
    [No Abstract]   [Full Text] [Related]  

  • 14. Histiocytic sarcoma arising from clonally related mantle cell lymphoma.
    Hure MC; Elco CP; Ward D; Hutchinson L; Meng X; Dorfman DM; Yu H
    J Clin Oncol; 2012 Feb; 30(5):e49-53. PubMed ID: 22184374
    [No Abstract]   [Full Text] [Related]  

  • 15. Retroperitoneal Bulky Histiocytic Sarcoma Successfully Treated with Induction Chemotherapy Followed by Curative Surgery.
    Oto M; Maeda A; Nose T; Ueda Y; Uneda S; Inadome A; Oshima K; Yoshida M
    Intern Med; 2017 Oct; 56(20):2765-2768. PubMed ID: 28924109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Remission with Novel Combined Immune-Targeted Treatment for Histiocytic Sarcoma Accompanied by Follicular Lymphoma: Case Report and Literature Review.
    Zhang M; Xiao F; Fang J; Liu Z; Shen Y; Zhu D; Zhang Y; Hou J; Huang H
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
    Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
    Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.
    Shroff RT; Yarchoan M; O'Connor A; Gallagher D; Zahurak ML; Rosner G; Ohaji C; Sartorius-Mergenthaler S; Parkinson R; Subbiah V; Zinner R; Azad NS
    Br J Cancer; 2017 May; 116(11):1402-1407. PubMed ID: 28441383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
    Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.